Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma

18 Feb 2021

Abstract excerpt

Abstract NSD2 is the primary oncogenic driver in t(4;14) multiple myeloma. Using SILAC-based mass spectrometry, we demonstrate a novel role of NSD2 in chromatin remodeling through its interaction with the SWI/SNF ATPase subunit SMARCA2. SMARCA2 was primarily expressed in t(4;14) myeloma cells, and its interaction with NSD2 was noncanonical and independent of the SWI/SNF complex. RNA sequencing identified PTP4A3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33602783
DOI: 10.1158/0008-5472.can-20-2946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple MyelomaPMID 33602783Read ↗

Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma.Semantic proximity Read ↗

NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma.Semantic proximity Read ↗

Expression Profile, Prognostic Value, and Therapeutic Potential of NSD2 in Pan-Cancer: A Systematic Analysis Integrating Multi-Omics DataSemantic proximity Read ↗

C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myelomaSemantic proximity Read ↗

REIIBP promotes TLR7-BTK-IL6 pro-inflammatory response through histone H3 lysine methylation in t(4;14) myelomagenesisSemantic proximity Read ↗

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMMSemantic proximity Read ↗

ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype.Semantic proximity Read ↗

Prognostic and Immunological Characterization of NSD3 Evaluated Through an Integrative Pan-Cancer AnalysisSemantic proximity Read ↗

A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.Semantic proximity Read ↗

SETD7 is a novel therapeutic target for multiple myeloma with t(11;14)+Semantic proximity Read ↗

Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genesSemantic proximity Read ↗

MMSET is the key molecular target in t(4;14) myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.